Notification of trade

Moss, 3 March 2025 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transactions have been completed: INSR AS and Norda ASA have each today purchased 614 251 shares in Gentian at NOK 46.50 per share. Following the transactions Insr ASA and Norda ASA own 614,251 shares each in Gentian Diagnostics ASA. Insr ASA and Norda ASA each own about 3.98% of the total outstanding shares following the transactions. Insr ASA and Norda ASA will together with the Group of companies Kvantia AS, Obligasjon 2 AS, Caaby AS, RWD AS and Victoria India Fund AS following the share transactions hold in total 3,422,370 shares in Gentian Diagnostics ASA, corresponding to approx. 22.2% of the total outstanding shares. Fredrik Thoresen is a board member and primary insider in Gentian. Please note that Fredrik Thoresen has no formal role in INSR ASA and Norda ASA. However, it could be claimed that Fredrik Thoresen has an impact on the investment decisions in INSR ASA and Norda ASA, therefore we send this notice in order to be transparent. PCA notification pursuant to the EU Market Abuse Regulation Article 19 is attached. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II. For further information, please contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25